In SURMOUNT-1 the dose of tirzepatide or matching placebo was escalated to 5 mg, 10 mg, or 15 mg subcutaneously once-weekly during a 20-week period followed by the maintenance period
Extracted data were organized into predefined thematic domains, including: (1) body composition changes associated with GLP-1 receptor agonist therapy, (2) molecular and physiological mechanisms of testosterone signaling in skeletal muscle, (3) clinical effects of TRT on lean mass and body composition in men with low testosterone, (4) obesity-related suppression of endogenous testosterone and metabolic interactions, and (5) safety considerations relevant to combined metabolic and endocrine management
Doctor of Oriental medicine, Gordana Smith is a certified AcuPoint Injection Therapist and has taken addition Advanced AcuPoint training for AIT
When you are eating and drinking even less than with either medication alone, UTI prevention through conscious hydration becomes even more important
Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D
10.1016/S0021-9258(17)37366-0 3 AstrupA